Adebrelimab plus etoposide for older or frail adults with small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs—adebrelimab (an immunotherapy) and etoposide (a chemotherapy pill)—for people with advanced small cell lung cancer who are older (65+) or not in good physical shape. The goal is to see if this treatment works well and is safe for patients who might not tolerate more intense therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage or locally advanced small cell lung cancer.
- You are either 65 years or older, or your daily performance status is poor (ECOG PS 2-3).
- You have at least one tumor that can be measured on imaging scans.
- Your doctors expect you to live more than 3 months.
- Your blood counts, liver, kidney, and heart function are within acceptable levels.
- You are willing to use effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (adebelimab) with chemotherapy as a first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard care.
This study tests a combination of three drugs (bevacizumab, anlotinib, and etoposide) as the first treatment for small-cell lung cancer that has spread. It is designed for older patients or those who cannot tolerate standard intensive chemotherapy, with the goal of controlling the cancer while being gentler on the body.
This trial tests a new combination of two targeted/immune drugs with standard chemotherapy as a first treatment for extensive small cell lung cancer. It aims to see if this approach is safe and effective for people who have not had prior treatment for this cancer.
This trial tests a new drug called Adebelizumab (an immunotherapy) combined with chemotherapy and radiation for people with extensive stage small cell lung cancer. The goal is to see if this combination helps shrink tumors and improves survival.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial tests a combination of two medicines (etoposide and benmelstobart) followed by a maintenance treatment with benmelstobart and anlotinib for older adults with extensive-stage small cell lung cancer. The goal is to see if this treatment helps control the cancer and is safe for patients who may not tolerate standard platinum-based chemo.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.